Literature DB >> 31266762

Renal stone composed of ritonavir.

Anna M Zhao1, Nancy R Angoff2.   

Abstract

Nephrolithiasis is a well-known side effect of many HIV protease inhibitors. However, there have not been reports of stones associated with ritonavir use. Here, we report the case of a 33-year-old woman with HIV on antiretroviral therapy who presented with sharp left flank pain and passed a stone that was later found to contain only ritonavir. Of note, the patient's treatment regimen had not included ritonavir for 2 years prior to this incidence. This case is notable both for the novel finding of a renal calculus composed entirely of ritonavir and the development of nephrolithiasis years after cessation of the aggravating drug. This finding suggests that patients on ritonavir should be more closely monitored and for longer periods of time for potential lithiasis formation. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  HIV/AIDS; renal system

Mesh:

Substances:

Year:  2019        PMID: 31266762      PMCID: PMC6605930          DOI: 10.1136/bcr-2019-230487

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  29 in total

1.  Atazanavir urinary stones in an HIV-infected patient.

Authors:  Jérôme Pacanowski; Jean-Marie Poirier; Isabelle Petit; Jean-Luc Meynard; Pierre-Marie Girard
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

2.  Atazanavir-containing renal calculi in an HIV-infected patient.

Authors:  Peter L Anderson; Kenneth A Lichtenstein; Nel E Gerig; Jennifer J Kiser; Lane R Bushman
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

3.  Renal failure after treatment with ritonavir.

Authors:  M Duong; C Sgro; M Grappin; F Biron; A Boibieux
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

4.  Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans.

Authors:  J F Denissen; B A Grabowski; M K Johnson; A M Buko; D J Kempf; S B Thomas; B W Surber
Journal:  Drug Metab Dispos       Date:  1997-04       Impact factor: 3.922

5.  Urolithiasis associated with the protease inhibitor indinavir.

Authors:  R G Bruce; L C Munch; A D Hoven; R S Jerauld; R Greenburg; W H Porter; P W Rutter
Journal:  Urology       Date:  1997-10       Impact factor: 2.649

Review 6.  The nephrotoxic effects of HAART.

Authors:  Hassane Izzedine; Marianne Harris; Mark A Perazella
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

7.  [Urinary lithiasis secondary to medication in HIV+ patients receiving Indinavir].

Authors:  Joaquín Ulises Juan Escudero; Emilio López Alcina; Felipe Ordoño Domínguez; Milagros Fabuel Deltoro; Francisco Serrano de la Cruz Torrijos; Ana Montoliu García; Francisco Ramada Benlloch; Emilio Marqués Vidal
Journal:  Arch Esp Urol       Date:  2008 Jan-Feb       Impact factor: 0.436

8.  Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.

Authors:  Kirk M Chan-Tack; Melissa M Truffa; Kimberly A Struble; Debra B Birnkrant
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

Review 9.  HIV medication-based urolithiasis.

Authors:  Hassane Izzedine; François Xavier Lescure; Fabrice Bonnet
Journal:  Clin Kidney J       Date:  2014-03-11

Review 10.  Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV.

Authors:  Milena M McLaughlin; Aimee J Guerrero; Andrew Merker
Journal:  Drugs Context       Date:  2018-03-21
View more
  1 in total

1.  Endourological management of a rare radiopaque ritonavir-composed urinary calculus.

Authors:  Folawiyo Laditi; Amir Ishaq Khan; Eric M Ghiraldi; Tashzna Jones; Ankur Choksi; Dinesh Singh
Journal:  Urol Case Rep       Date:  2021-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.